ProCE Banner Activity

Phase II FORTE: Efficacy of KRd With or Without ASCT in Newly Diagnosed Multiple Myeloma According to Risk Status

Slideset Download
Conference Coverage
Including ASCT after KRd induction therapy leads to higher persistent MRD negativity rate and reduces risk of early relapse in NDMM.

Released: June 03, 2019

Expiration: June 01, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro